These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34962151)

  • 1. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study.
    Davis G; Bailey R; Calhoun P; Price D; Beck RW
    Diabetes Technol Ther; 2022 May; 24(5):324-331. PubMed ID: 34962151
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial.
    Martens T; Beck RW; Bailey R; Ruedy KJ; Calhoun P; Peters AL; Pop-Busui R; Philis-Tsimikas A; Bao S; Umpierrez G; Davis G; Kruger D; Bhargava A; Young L; McGill JB; Aleppo G; Nguyen QT; Orozco I; Biggs W; Lucas KJ; Polonsky WH; Buse JB; Price D; Bergenstal RM;
    JAMA; 2021 Jun; 325(22):2262-2272. PubMed ID: 34077499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring.
    Bailey R; Calhoun P; Chao C; Walker TC
    Diabetes Technol Ther; 2022 Apr; 24(4):281-284. PubMed ID: 34704817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial.
    Laffel LM; Kanapka LG; Beck RW; Bergamo K; Clements MA; Criego A; DeSalvo DJ; Goland R; Hood K; Liljenquist D; Messer LH; Monzavi R; Mouse TJ; Prahalad P; Sherr J; Simmons JH; Wadwa RP; Weinstock RS; Willi SM; Miller KM; ;
    JAMA; 2020 Jun; 323(23):2388-2396. PubMed ID: 32543683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial.
    Lind N; Christensen MB; Hansen DL; Nørgaard K
    Diabetes Care; 2024 May; 47(5):881-889. PubMed ID: 38489032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin.
    Bao S; Bailey R; Calhoun P; Beck RW
    Diabetes Technol Ther; 2022 May; 24(5):299-306. PubMed ID: 34939824
    [No Abstract]   [Full Text] [Related]  

  • 7. Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program.
    Billings LK; Parkin CG; Price D
    Diabetes Technol Ther; 2018 Aug; 20(8):561-565. PubMed ID: 30044123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
    Messer LH; Buckingham BA; Cogen F; Daniels M; Forlenza G; Jafri RZ; Mauras N; Muir A; Wadwa RP; White PC; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro CA; Li Z; Marak MC; Calhoun P; Beck RW
    Diabetes Technol Ther; 2022 Oct; 24(10):712-725. PubMed ID: 36173237
    [No Abstract]   [Full Text] [Related]  

  • 9. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin.
    Aleppo G; Beck RW; Bailey R; Ruedy KJ; Calhoun P; Peters AL; Pop-Busui R; Philis-Tsimikas A; Bao S; Umpierrez G; Davis G; Kruger D; Bhargava A; Young L; Buse JB; McGill JB; Martens T; Nguyen QT; Orozco I; Biggs W; Lucas KJ; Polonsky WH; Price D; Bergenstal RM; ;
    Diabetes Care; 2021 Dec; 44(12):2729-2737. PubMed ID: 34588210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THE ADDED AND INTERPRETATIVE VALUE OF CGM-DERIVED PARAMETERS IN TYPE 1 DIABETES DEPENDS ON THE LEVEL OF GLYCEMIC CONTROL.
    Helleputte S; De Backer T; Calders P; Pauwels B; Shadid S; Lapauw B
    Endocr Pract; 2021 Jan; 27(1):44-50. PubMed ID: 33475500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic Control in Relation to Technology Use in a Single-Center Cohort of Children with Type 1 Diabetes.
    Sawyer A; Sobczak M; Forlenza GP; Alonso GT
    Diabetes Technol Ther; 2022 Jun; 24(6):409-415. PubMed ID: 35099306
    [No Abstract]   [Full Text] [Related]  

  • 14. Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus.
    Kurozumi A; Okada Y; Mita T; Wakasugi S; Katakami N; Yoshii H; Kanda K; Nishida K; Mine S; Tanaka Y; Gosho M; Shimomura I; Watada H
    Diabetes Res Clin Pract; 2022 Apr; 186():109836. PubMed ID: 35314256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range.
    Puhr S; Calhoun P; Welsh JB; Walker TC
    Diabetes Technol Ther; 2018 Aug; 20(8):557-560. PubMed ID: 30036082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial.
    Visser MM; Charleer S; Fieuws S; De Block C; Hilbrands R; Van Huffel L; Maes T; Vanhaverbeke G; Dirinck E; Myngheer N; Vercammen C; Nobels F; Keymeulen B; Mathieu C; Gillard P
    J Diabetes Sci Technol; 2024 May; 18(3):660-666. PubMed ID: 36172693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial.
    Pratley RE; Kanapka LG; Rickels MR; Ahmann A; Aleppo G; Beck R; Bhargava A; Bode BW; Carlson A; Chaytor NS; Fox DS; Goland R; Hirsch IB; Kruger D; Kudva YC; Levy C; McGill JB; Peters A; Philipson L; Philis-Tsimikas A; Pop-Busui R; Shah VN; Thompson M; Vendrame F; Verdejo A; Weinstock RS; Young L; Miller KM;
    JAMA; 2020 Jun; 323(23):2397-2406. PubMed ID: 32543682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.
    Vigersky RA; McMahon C
    Diabetes Technol Ther; 2019 Feb; 21(2):81-85. PubMed ID: 30575414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial.
    Ekhlaspour L; Town M; Raghinaru D; Lum JW; Brown SA; Buckingham BA
    Diabetes Technol Ther; 2022 Aug; 24(8):588-591. PubMed ID: 35020488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.